TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

Teva to Present at the Jefferies London Healthcare Conference

08 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

06 Nov 2024 09:46:07 By NetDania Notify

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

01 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

01 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

Teva Statement on European Commission Decision; Company to Appeal

31 Oct 2024 07:29:54 By Nasdaq GlobeNewswire

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

22 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

08 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

03 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

01 Oct 2024 08:29:04 By Nasdaq GlobeNewswire

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

30 Sep 2024 16:30:00 By Nasdaq GlobeNewswire

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

23 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

21 Sep 2024 04:15:00 By Nasdaq GlobeNewswire

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

21 Sep 2024 04:10:00 By Nasdaq GlobeNewswire

Teva to Present at the Bank of America 2024 Global Healthcare Conference

11 Sep 2024 16:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

04 Sep 2024 09:49:14 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

27 Aug 2024 12:25:53 By NetDania Notify

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

26 Aug 2024 17:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

26 Aug 2024 09:45:30 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

15 Aug 2024 09:45:04 By NetDania Notify